Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07187921 · ClinicalTrials.gov registry record
Evaluation of a Finger Prick Collection Method for Measuring Alzheimer's Disease Blood Biomarkers
A clinical trial, sponsored by Banner Health.
- Completed
- Registry status
- 49
- Enrollment target
NCT07187921: Completed study, sponsored by Banner Health.
NCT07187921 is a clinical trial that has completed, run by Banner Health. The registered enrollment target is 49 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07187921 has completed, sponsored by Banner Health.
- COMPLETED
- Registry status
- 49 participants
- Enrollment target
Study Summary
This is an observational study that will collect blood from a finger prick (Capitainer SEP10 single channel device) and assess the accuracy of pTau-217 testing in comparison to previously collected venous blood samples from the same individuals.
Primary Outcome
compare pTau-217 assay value from finger prick blood sample to assay value from previously collected venipuncture-based collected blood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2025-09-29 |
| Est. Completion | 2025-11-12 |
What the finished NCT07187921 record still lists
NCT07187921 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 49 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT07187921 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07187921 about?
NCT07187921 is a clinical study titled "Evaluation of a Finger Prick Collection Method for Measuring Alzheimer's Disease Blood Biomarkers". This is an observational study that will collect blood from a finger prick (Capitainer SEP10 single channel device) and assess the accuracy of pTau-217 testing in comparison to previously collected venous blood samples from the same individuals.
What is the current status of trial NCT07187921?
This trial is currently completed. The enrollment target is 49 participants. The study started on 2025-09-29. Estimated completion is 2025-11-12.
Who is sponsoring clinical trial NCT07187921?
This trial is sponsored by Banner Health, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI